Press Release Archive
Press Releases
November 2018
11.26.2018 Medicines Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall Of Six Lots Of ThermaCare® HeatWraps Due To Leaking Wraps with the Potential For Skin Injuries 11.21.2018 Medicines U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option 11.19.2018 Research Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer 11.16.2018 Finance Pfizer Provides Transparency On Drug Prices In The U.S. 90 Percent Of Company’s Prices Will Remain Unchanged 11.11.2018 Research Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation 11.09.2018 Research Data From Phase 2 PALLET Study of IBRANCE® (palbociclib)in Early Breast Cancer to be Presented at San Antonio Breast Cancer Symposium 11.02.2018 Medicines U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
October 2018
10.30.2018 Finance PFIZER REPORTS THIRD-QUARTER 2018 RESULTS 10.28.2018 Research Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH 10.25.2018 Partnerships CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL CANCER DRUGS 10.23.2018 Research Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients 10.23.2018 Partnerships Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.